Gianfranco Nazzi – CEO, Almirall
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Almirall, S.A. is a Spanish pharmaceutical company, with headquarters in Barcelona, founded in 1943.[4]
In 2016, it generated a total revenue of 859.3 million € [5] and became the leading pharmaceutical company in R&D investment in Spain.
With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and the United States.
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona in Spain. Highlighted among the international alliances are those with the Imperial College of London (United Kingdom) and the National Institute of Health (NIH) in the United States. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Rui Ferreira Dos Santos, country manager for Spanish pharmaceutical company, Almirall provides readers with an update on the company’s new medicines and how their global strategy to become dermatology specialists…
Bertil Lindmark, Almirall’s chief scientific officer, discusses the state of R&D in Spain today and outlines the key strategies the company is taking to provide valuable medicines and cutting-edge technologies…
Eduardo Sanchiz took over as CEO of Spain’s flagship pharmaceutical company Almirall in 2011, after Jorge Gallardo stepped down in this role while staying as Chairman of the Board. Many…
Israel Garcia, general manager of Spain for Almirall, discusses market access issues in the company’s home country and highlights the affiliate’s commitment to internal R&D. What was the reason for…
Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well…
Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today?…
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
Roland Wandeler, general manager of Amgen Iberia, discusses the affiliate’s commitment to innovation, clinical trials, and the importance of providing both medicines and solutions in order to foster a more…
Roland Wandeler, general manager of Amgen Iberia, discusses the affiliate’s commitment to innovation, clinical trials, and the importance of providing both medicines and solutions in order to foster a more…
Ricardo Brage serves as Vice President Spain for Sanofi Pasteur MSD. He discusses how he sought to change the subsidiary in response to pricing reforms as well as the challenges…
Joan Guinovart, director of the Institute for Research in Biomedicine in Barcelona (IRB Barcelona), discusses the Institute’s unique interdisciplinary characteristics and emphasises the need for Spain to foster technology transfer…
The head of strategic initiatives at the Basque Business Development Agency talks about the region’s strong commitment to developing its biosciences sector, the cluster strategy the region has implemented in…
Life Length was founded through the CNIO (Spanish National Cancer Research Center) combined with the support of the Botín Foundation, Matlin Associates and Dr. Maria Blasco’s work in telomeres. Stephen…
Manuel Hidalgo, director of the Centro Integral Oncológico Clara Campal (CIOCC), discusses the expansion of the private sector of hospitals in Spain and the latest developments that CIOCC has taken…
When Jordi Martí came to Celgene in December 2012, one of his main goals was to create a change in the affiliate’s model. The VP Managing Director of Celgene Spain…
When Jordi Martí came to Celgene in December 2012, one of his main goals was to create a change in the affiliate’s model. The VP Managing Director of Celgene Spain…
NIMGenetics is a leading Spanish company in the area of genetic diagnostics. The company’s president and CEO, Enrique Samper, traces the evolution of NIMGenetics over the last four years, its…
Luis Serrano, director of the Centre for Genomic Regulation in Barcelona, discusses improvements in technology transfer, Catalunya’s competitiveness in research, and Spain’s transformation from a follower to a leader in…
Despite the crisis in Spain, local Spanish companies continued to succeed in exports and general internationalization. Maria del Coriseo, CEO of local investment agency ICEX, outlines the successes of these…
See our Cookie Privacy Policy Here
